Getting your Trinity Audio player ready...

As the trading week finally comes to a close, it could well be a good time for investors to consider taking a look into those stocks that have hit the news cycle and made headlines. There were many stocks that had been able to do that, but this feature would provide you with a look into four select stocks that did.

Intelligent Bio Solutions Inc. (NASDAQ:INBS) The medical technology company, which is involved in providing fast, intelligent, and non-invasive testing solutions, was in focus on October 24 following a key announcement. Intelligent Bio Solutions Inc. revealed that it had expanded into the lucrative New Zealand market.

In the news release, it was noted that the expansion was a major new milestone in its growth strategy pertaining to its Intelligent Fingerprinting Drug Screening System. The economic harm created by drugs in New Zealand is pegged at $1.9 billion a year, and hence it is a market that may be ripe for the company’s testing system.

Clean Vision Corporation (OTC:CLNV) is an emerging leader in the sustainable green energy and clean technology sectors. On October 24, Clean Vision Corporation announced the makeup of the development and engineering support team for the plastic conversion manufacturing project of Clean-Seas Virginia, its fully owned subsidiary.

The project is located in Quincy, West Virginia. The company announced that it chose CDI Engineering Solutions for engineering, construction, and procurement services and ERM for environmental and permitting support. Additionally, it was also revealed that Bowles Rice LLP had been selected as legal and regulatory advisors for the team.

Futuris Company (OTC:FTRS) In the last reporting period that ended on July 31, 2023, the OTC Markets listed company recorded revenues in excess of $40 million and net profit to the tune of $2.9 million. In a recorded webinar that was released on October 23, Robert Day, the Chief Executive Officer of Futuris Company, discussed how the company hit profitability.

He noted that the company managed to do so through the acquisition of more revenue-generating and profitable companies. He also spoke about his confidence in the future of the company.

ImmunityBio Inc. (NASDAQ:IBRX) The clinical-stage immunotherapy company hit the headlines on October 26 after it made a major new announcement. ImmunityBio Inc. revealed that its resubmission of the Biologics License Application for its product N-803 had been accepted by the United States Food and Drug Administration.

The agency provided the company with a fee goal date of April 23, 2024. The company’s resubmission had been accepted as a complete response following discussions between the two parties.